Skip to main content
Delfa

← All assets

Verdiperstat

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

1

Recruiting

0

Completed

0

Sites

5

Countries

1

Endpoints

13

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 13 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1

Trials by status

Active, not recruiting
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Executive function / language
4
Neuroimaging
2
Safety / tolerability / PK
2
Global cognition
1
Behavior / neuropsychiatric
1
Neurodegeneration biomarkers
1
Fluid / digital biomarkers
1
Other (unclassified)
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 3 of 13 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neurofilament light (NfL)Neurodeg.

1

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

1

Neuropsychiatric Inventory (NPI)Behavior

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
Veri-T-001Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Verdiperstat

Frontotemporal dementia

Study partner/caregiver requiredPh 1Active, not recruiting5Jan 2027-

Showing 1-1 of 1 trials